Wijziging van de Wet geneesmiddelenprijzen in verband met een aanpassing van de referentielanden

This procedure concerns an amendment to the Dutch Medicine Prices Act. It aims to update the list of reference countries used to determine and calculate the maximum prices for pharmaceuticals within the Netherlands. This change affects pharmaceutical companies and healthcare payers by altering the pricing benchmark used to regulate medicine costs in the Dutch market.